<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Bee Sting Vaccine History</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <header>
        <h1>Bee Sting Vaccine History</h1>
        <nav>
            <a href="https://chatgptcodedstuff.github.io/Bee-Vaccine/">Home Page</a>
        </nav>
    </header>
    <main>
        <section>
            <h2>Pioneering Venom Immunotherapy (VIT)</h2>
            <p>
                The first form of VIT was pioneered by Dr. LIB Braun to treat patients with severe allergic reactions to insect stings. One notable case involved a patient who had experienced increasingly severe reactions after multiple stings. To address this, Dr. Braun began administering diluted bee venom through injections to desensitize her body. Gradually, he increased both the concentration and volume of the venom. Remarkably, this approach allowed her to tolerate up to 1.5 cc of venom with only mild reactions occurring approximately 10 minutes afterward.
            </p>
            <div class="images">
                <img src="https://tse1.mm.bing.net/th/id/OIP.0GYVBuWvThonPCHanYFuzAHaHa?w=220&h=220&c=7&r=0&o=5&pid=1.7" alt="Bee">
                <img src="https://cdn-icons-png.flaticon.com/512/2232/2232683.png" alt="History">
            </div>
        </section>
        <section>
            <h2>Mary Loveless's Contributions</h2>
            <p>
                Venom immunotherapy was refined by Mary Loveless in 1948. Initially, she used whole-body extracts, but after conducting a chemical analysis, she realized that pure venom might be more effective. In 1953, Loveless began an experiment injecting patients with progressively increasing doses of pure venom. While her early tests sometimes induced reactions, by 1956, she had perfected the technique and published a groundbreaking paper, which was eventually accepted by the medical community.
            </p>
        </section>
        <section>
            <h2>Evolution of Venom Immunotherapy</h2>
            <p>
                Historically, VIT utilized Whole Body Extracts (WBEs) until the late 1900s. These extracts consisted of a mixture of venom components and were the standard treatment method for many years. However, as research progressed, new methods emerged. Mary Hewitt Loveless's influential article advocated for the use of venom sacks instead of WBEs, highlighting the advantages of using purified venom components for more effective treatment.
            </p>
        </section>
        <section>
            <h2>Omalizumab in VIT</h2>
            <p>
                Omalizumab, a monoclonal antibody initially developed for asthma, has been integrated into VIT to enhance patient tolerance and reduce allergic reactions. Omalizumab binds to immunoglobulin E (IgE), preventing it from attaching to cells and causing allergic reactions. This allows patients to reach higher treatment levels faster with fewer reactions, making it easier for those with severe allergies to use immunotherapy.
            </p>
        </section>
        <section>
            <h2>History of Bee Sting Vaccines</h2>
            <p>
                The history of bee sting vaccines dates back to the early 20th century when the medical community began understanding and addressing the dangers of severe allergic reactions to bee stings (anaphylaxis). In the early 1900s, bee venom was used in therapeutic practices, notably by Polish physician Jan Mikulicz-Radecki. Serious development of vaccines aimed at treating severe allergic reactions began in the 1950s and 1960s, involving gradually exposing individuals to small amounts of bee venom in controlled environments to build up tolerance.
            </p>
            <p>
                By the 1970s and 1980s, significant strides were made in developing standardized and effective bee venom immunotherapy. Treatments involved a series of injections over several months, starting with very diluted doses of venom, which progressively increased. The 1990s and 2000s saw improvements in standardized venoms and understanding the immunological mechanisms behind allergic reactions. By the 21st century, VIT became a widely accepted and effective approach for preventing fatal anaphylaxis from bee stings. Researchers continue to explore potential improvements, including oral or more convenient forms of immunotherapy and genetically engineered therapies.
            </p>
        </section>
    </main>
    <footer>
        <p>&copy; 2025 Bee Sting Vaccine History. All rights reserved.</p>
    </footer>
</body>
</html>
